KCM
RARE icon

Kornitzer Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Kornitzer Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-58,125
Closed -$4.44M – 491
2018
Q3 		$4.44M Hold
58,125
– – 0.07% 255
2018
Q2 		$4.47M Sell
58,125
-14,185
-20% -$916K 0.07% 250
2018
Q1 		$3.69M Buy
+72,310
New +$3.64M 0.06% 273

Other funds holding RARE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Kornitzer Capital Management's RARE Position: Q4 2018 in Review

Kornitzer Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2018, closing a stake of 58,125 shares — an estimated $4.44M sold.

Kornitzer Capital Management first reported a position in RARE in Q1 2018 and held it in 3 quarters. The position peaked at $4.47M in Q2 2018. 164 funds tracked by Wall St. Rank hold RARE as of Q4 2018.

  • Kornitzer Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • Kornitzer Capital Management sold 58,125 Ultragenyx Pharmaceutical shares in Q4 2018, an estimated $4.44M.
  • Kornitzer Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and held it in 3 quarters.
  • Kornitzer Capital Management's Ultragenyx Pharmaceutical position peaked at $4.47M in Q2 2018.
  • 164 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2018.

Based on Kornitzer Capital Management's 13F filing for Q4 2018, filed 31 Jan 2019.